



THE 34th TEL AVIV UNIVERSITY AD AND RELATED NEURODEGENERATIVE DISEASES CONFERENCE

Program

Wednesday, June 3, 2026

In memory of Prof. Danny Michaelson

Steinhardt Museum of Natural History, Tel Aviv University Campus

08:30 -08:45

Registration, Coffee



08:45- 09:00

Welcome and opening presentation:

Dan Peer, TAU VP for research and development

Amos D Korczyn

Reuven Stein

Session 1:

Chairs: Reuven Stein, Yoav Gothilf

09:00-09:25

Yvonne Freund-Levi

Why Lipids in Alzheimer Disease? Biological Background and Clinical Findings from the OmegAD trial

09:25-09:50

Tobias Hartmann

The EU - teamwork project "Therapeutic and preventive impact of nutritional lipids on AD (LipDiDiet)" History, current results and future

09:50-10:15

Hussein Yassine

Brain cholesterol metabolism in APOE4, from basic science to clinical trials

10:15-10:40

Ornit Chiba-Falek

Transforming Alzheimer's Disease Drug Discovery through Single-Cell Multi-Omics: Insights into APOE Genomics and Therapeutic Potential

- 10:40-11:00 Joab Chapman**
Autoimmune Dementia- From Vision to Reality
- 11:00-11:20 Ronit Pinkas- Kramarski**
APOE4 and autophagy in neurodegenerative diseases
- 11:20-11:40 Judith Aharon Peretz**
Bench to patients: the evolving narrative of Alzheimer disease

- 11:40-12:10 Coffee break** 

Session 2:

Chairs: Yoav Henis, Ari Barzilai

- 12:10-12:30 Roy Rabinowitz**
CRISPR strategies to target and convert APOE4 -
My journey with Danny Michaelson
- 12:30-12:50 Anan Moran**
How the taste system can help us study Alzheimer disease
- 12:50-13:10 Pablo Blinder**
Impact of ApoE4 on perineuronal net spatio-temporal stability
- 13:10-13:20 Amit Koren Iton**
Detecting subtle behavioral deficits in apoE models: a topological perspective from spatial navigation
- 13:20-13:30 Roni Bar**
ApoE4 alters long-chain triacylglycerol composition of astrocyte-derived ApoE Particles
- 13:30-13:40 Hila Ben-Moshe**
Targeting apoE4 Lipidation: From High-Throughput Screening to In Vivo Phenotypic Rescue
- 13:40-13:50 Anat Boehm**
A drug, the regulator and the public: a use case analysis of Aduhelm and its implications on the AD field
- 13:50-14:00 Shiran Zimri**
From Inspiration to Innovation: Matrix Thinking from Discovery to Drug Development
- 14:00-14:40 Lunch** 

Session 3:

Danny Michaelson's Excellence Award in Alzheimer Disease Research

Chairs: Uri Ashery, Dan Frenkel

14:40-14:55 Award ceremony

Lectures by award recipients

14:55-15:05 Lior Nechushtai
APOE4-expressing astrocytes exhibit Parkinson's disease-related pathology

15:05-15:15 Rotem Falach
From Hippocampus to Surface: Zygomatic Sleep EEG Detection of Epileptiform Activity in MCI

15:15-15:25 Elisa Gozlan
Senescent microglia / monocytes exacerbate cognitive impairment in 5XFAD mice

15:25-15:35 Yuliya Androsova
Immunotherapy clears senescent microglia, a key driver of Alzheimer disease progression

15:35-15:45 Halit baeloha
Targeting the nucleus reuniens to improve memory and synaptic function in AD

15:45-15:55 Emmanuel O. Chidebe
Doxycycline as a Tool to Model Post-Infection Neuroinflammation: Microglial and Neuronal response in Neurodegenerative Disease

15:55-16:05 Artur Galushkin
Circadian Control of Behaviour Associated with Alzheimer Disease Somatic Mutations Impacting the Cytoskeleton

Thursday, June 4, 2026

The Raya and Josef Jaglom Auditorium , George S. Wise Senate Building

08:30 -08:45 Registration, Coffee



08:45- 09:00 Welcome and opening presentation:

Karen Avraham, Dean, Gray Faculty of Medical and Health Sciences

Tamara Shiner, Dan Frenkel

Session 1:

Chairs: Abraham Fisher, Menahem Segal

09:00-09:20 Noa Bregman

Lecanemab in Practice: AI-Derived MRI Predictors of Benefit and Amyloid Related Imaging Abnormalities (ARIA)

09:20-09:40 Tamara Shiner

Updates in Dementia with Lewy Bodies: Genetics, Biomarkers, and Therapeutics

09:40-10:00 Eitan Auriel

Cerebral small vessel disease

10:00-10:20 Rafi Hadad

Frontotemporal Dementia and LATE: Recent Advances and What Matters Now

10:20-10:40 Shahar Arzy

Multilevel computational approach towards personalized medicine in AD

10:40-11:00 Eli Wertman

The clinical definition of Alzheimer Disease and its effect on treatment in the blood biomarker era

11:00-11:30 Coffee break



Session 2:

Chairs: Beka Solomon, Yvonne Freund-Levi

11:30 – 11:50 Michal Schwartz

Unleashing the systemic immune system by blocking inhibitory checkpoints in AD : dampening neuroinflammation and rescuing neurons and function

11:50- 12:10 Hermona Soreq

Molecular stress responses and neurodegenerative diseases

- 12:10 – 12:30 Illana Gozes**
Sex Specific Therapeutics Targeting Tau: The Case of ADNP, Davunetide and APOE
- 12:30 – 12:50 Iftach Shaked**
Acute glucose spikes fan the flames of brain inflammation
- 12:50 - 13:10 Or Shemesh**
Alzheimer Disease as an Infectious-Immune Disorder: How Microorganisms May Initiate and Shape Neurodegeneration
- 13:10-13:30 David Gurevich**
Reduced taurine transporter expression in immune-derived cell lines therapy from Alzheimer's Disease patients: a window for novel AD
- 13:30 – 13:50 Eitan Okun**
Fetomaternal Transfer of Human APP During Pregnancy Drives Lasting Maternal Cognitive Decline and Neuroinflammation

13:50 – 14:30 Lunch



Session 3:

Herczeg Institute on Aging

Chair: Debbie Rand

Winners of a scholarship in aging research

- 14:30- 14:40 Matan Gabay**
Engineering Next-Generation CTLA4 Therapeutics for Rheumatoid Arthritis
- 14:40-14:50 Tali Geffen**
Environmental Barriers and Participation in Older Adults: The Mediating Role of Resilience
- 14:50-15:00 Elisa Gozlan**
The link between expression of p16 in astrocytes and brain pathology in AD
- Short poster presentations**
- 15:00-15:05 David Kaminskiy**
New model to assess the effect of loss in insulin signaling on neurodegeneration in AD
- 15:05-15:10 Liri Sophia Guz**
Potential estrogen replacement therapy
- 15:10-15:15 Alexandra Lobyntseva**
Peptide-functionalized nanocarriers for enhanced RNA delivery to the brain

Session 4:

Chairs: Noa Bregman, Rafi Hadad

- 15:15-15:35 Daniel Harlev**
Dissociating Effort and Reward: A Computational Approach to Apathy, Mild Behavioral Impairment, and Cognitive Decline Shape Neurodegeneration
- 15:35-15:55 Haim Belmaker**
Lithium and Alzheimer's: A sceptical perspective
- 15:55- 16:15 Katarzyna Ciesla**
Frontal cerebral perfusion compensates for metabolic burden to preserve memory in midlife adults at AD risk: a 3D arterial spin labeling study
- 16:15- 16:35 Chen Duksin**
Eisai Alzheimer's Disease Pipeline

Session 5

- 16:35-17:15 Round table:**
Bench to Bedside- Gaps between Physicians and Basic Science Researchers
Amos Korczyn, Abraham Fisher, Yvonne Freund-Levi, Illana Gozes
Moderator: Tamara Shiner
- 17:15 Concluding remarks**
Amos Korczyn ,Tamara Shiner, Dan Frenkel

With thanks to our sponsors

- Tel Aviv University
- The Herczeg Institute on Aging
- Prajs-Drimmer Institute for Development of Anti-Degenerative Drugs
- Rabin Institute of Neurobiology
- The Albert and Alba Cuenca Research Institute for Treatment Approaches to Age-Related Diseases
- The national institute for psychobiology in Israel

- Teva 

- Eisai Israel Ltd  
human health care

- Eli Lilly Company  A MEDICINE COMPANY